IPF / ILD Working Group


  • Luca Richeldi – Lead
  • Katerina Antoniou
  • Arata Azuma
  • Jürgen Behr
  • Demosthenes Bouros
  • Kevin Brown
  • Harold Collard
  • Tamera Corte
  • Ulrich Costabel
  • Ian Glaspole
  • Vincent Cottin
  • Bruno Crestani
  • Kevin Flaherty
  • Michael Keane
  • Gisli Jenkins
  • Martin Kolb
  • Toby Maher
  • Fernando J. Martinez
  • Mariano Mazzei
  • Ferran Morell
  • Maria Molina
  • Steven Nathan
  • Christopher Ryerson
  • Ganesh Raghu
  • Paola Rottoli
  • Moises Selman
  • Carlo Vancheri
  • Athol U. Wells
  • Simon Walsh
  • Aileen David-Wang
  • Alan Kaplan
  • Andrew Wilson
  • Camilo Roa
  • Giovanni Ferrara
  • Jeff Myers
  • Kaissa DeBoer
  • Magnus Skold
  • Manuela Funke-Chambour
  • Thomas Geiser


The last meeting took place during the ERS 2016 in London, UK.

Work Plan

The IPF (Idiopathic Pulmonary Fibrosis) / ILD (Interstitial Lung Disease) Working Group believe that the introduction of licensed therapies for IPF place increasing emphasis on the need for earlier and more accurate diagnosis. The group believes there is a need to better understand current practice, (i.e. what is happening in the real-world) with a view to introducing appropriate treatments early to optimize potential therapeutic benefit and that these studies involve characterising real-world clinical practice and evaluating effectiveness (not drug efficacy).


Working Group Documents

Useful Links